NEW YORK (GenomeWeb News) – Genome engineering firm Cellectis on Thursday reported that its total operating revenues slipped 8 percent year over year during the first half of 2013.

For the first six months of the year, the Paris-based firm brought in €6.9 million ($9.4 million) in operating revenues, compared to €7.5 million during the first half of 2012. Operating revenues for the recently completed period comprised €2.8 million in sales, down from €3.1 million a year ago, and €4.1 million in other operating revenues, down from €4.4 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.